Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.
Biomarker and diagnostic research for lymphoplasmacytic lymphoma has been reported in the published literature.
No approved treatments are currently available for lymphoplasmacytic lymphoma. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for lymphoplasmacytic lymphoma, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for lymphoplasmacytic lymphoma. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
74 clinical trials registered, 26 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 1 PHASE3, 29 PHASE2, 25 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT01804686](https://clinicaltrials.gov/study/NCT01804686) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:00 AM UTC
Designated
Exclusivity End |
|---|
Designation Status |
|---|
18-(p-[131I]-iodophenyl)octadecyl phosphocholine | 18-(p-[131I]-iodophenyl)octadecyl phosphocholine | Cellectar Biosciences, Inc. | 2019 | — | Designated |
idelalisib | idelalisib | Gilead Sciences, Inc. | 2013 | — | Designated |
Gene therapy approaches for lymphoplasmacytic lymphoma have been reported in the published literature.
74 trials found
A Long-term Extension Study of PCI-32765 (Ibrutinib) |
PHASE3 |
Janssen Research & Development, LLC |
RECRUITING |
[NCT05602363](https://clinicaltrials.gov/study/NCT05602363) | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | PHASE1 | Carna Biosciences, Inc. | RECRUITING |
[NCT04883437](https://clinicaltrials.gov/study/NCT04883437) | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | PHASE2 | Emory University | RECRUITING |
[NCT00923507](https://clinicaltrials.gov/study/NCT00923507) | Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) | — | National Heart, Lung, and Blood Institute (NHLBI) | RECRUITING |
[NCT04061512](https://clinicaltrials.gov/study/NCT04061512) | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia | PHASE2 | University College, London | RECRUITING |
188 publications have been identified in PubMed for lymphoplasmacytic lymphoma. Research spans Case Report / Case Series (47%), Review / Meta-Analysis (15%), and Clinical Trial Publication (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 89 | 47% |
Research summaries | 28 | 15% |
Clinical study results | 20 | 11% |
Disease patterns and progression | 19 | 10% |
Testing and diagnosis research | 17 | 9% |
Laboratory research | 10 | 5% |
New treatment approaches | 3 | 2% |
Other research | 2 | 1% |
Dent M (2026). [PMID: 42005807](https://pubmed.ncbi.nlm.nih.gov/42005807/). *Gynecol Oncol Rep*. [Case Report / Case Series]
Chi H (2026). [PMID: 42182594](https://pubmed.ncbi.nlm.nih.gov/42182594/). *ACG Case Rep J*. [Case Report / Case Series]
Zhou XX (2026). [PMID: 42297589](https://pubmed.ncbi.nlm.nih.gov/42297589/). *Zhonghua Yi Xue Za Zhi*. [Diagnostic / Biomarker]
Imai M (2026). [PMID: 41252924](https://pubmed.ncbi.nlm.nih.gov/41252924/). *Annals of diagnostic pathology*. [Case Report / Case Series]
Wang H (2026). [PMID: 42266666](https://pubmed.ncbi.nlm.nih.gov/42266666/). *Front Oncol*. [Case Report / Case Series]
Mäkelä E (2026). [PMID: 41519657](https://pubmed.ncbi.nlm.nih.gov/41519657/). *Clin Lymphoma Myeloma Leuk*. [Epidemiology / Natural History]
Chen C (2026). [PMID: 41974312](https://pubmed.ncbi.nlm.nih.gov/41974312/). *Hum Pathol*. [Epidemiology / Natural History]
Guijosa A (2026). [PMID: 40681432](https://pubmed.ncbi.nlm.nih.gov/40681432/). *Clinical lymphoma, myeloma & leukemia*. [Clinical Trial Publication]
Willman GH (2026). [PMID: 41729267](https://pubmed.ncbi.nlm.nih.gov/41729267/). *Virchows Archiv : an international journal of pathology*. [Case Report / Case Series]
Webb CB (2026). [PMID: 41856840](https://pubmed.ncbi.nlm.nih.gov/41856840/). *Vet Clin North Am Small Anim Pract*. [Review / Meta-Analysis]
AI-curated news mentioning lymphoplasmacytic lymphoma
Updated Mar 10, 2026
A recent case report highlights the occurrence of severe aplastic anemia in a patient concurrently diagnosed with lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia. This finding may provide insights into the complex interplay between these hematological conditions.
A new case report details lymphoplasmacytic lymphoma associated with spherocytosis, contributing to the understanding of this rare disease. This finding may provide insights for future research and clinical considerations.